//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon


Online Registration is Open!
Register by Friday, February 26 to Save Up to $500!
»Pricing Chart

Add to Outlook Calendar

Find Another IBC Event

Bioconjugates: From Targets to Therapeutics


Transitioning Innovation into Viable Therapeutic Candidates

June 13-15, 2016
Parc 55 Hilton
San Francisco, CA

Event Overview

Event Overview

Taking innovative ideas from inception to the clinic with the latest breakthroughs and conjugation strategies including ADCs, conjugated vaccines, nanoparticle conjugates, and many more.

With the latest insights and advances in conjugation strategies; IBC's Bioconjugates: From Targets to Therapeutics conference will deliver:

  • Interactive formats to discuss and develop solutions to major roadblocks in conjugation techniques, CMC strategies, and process development including roundtable lunch discussions, panel discussions, and think tanks
  • Case studies and new data on novel linkers, new payloads, and alternative binding modalities to improve the discovery development process
  • Hear from the experts in ADCs to gain insights on navigating the regulatory approval process, process development, and development strategies for second generation ADCs
  • Go beyond ADCs and hear the latest advances in bispecific conjugation, nanoparticle conjugates, conjugated vaccines, and much more

Meet the 2016 Bioconjugates Advisory Board!

  • Dimiter Dimitrov, PhD., Senior Investigator, Protein Interactions, National Cancer Institute, NIH
  • Ho Cho, PhD., Executive Director, Biotherapeutics, Celgene Corporation
  • Alan C. Rigby, PhD, Vice President, ADC Biology, Lilly
  • Justin Sperry, Senior Principal Scientist, Pfizer
  • Steve Kolodziej, Associate Research Fellow, Pfizer
  • Bradley Pentelute, Ph.D., Pfizer-Laubach Career Development, Professor, Associate Member, Board Institute of Harvard and MIT; Member, Center for Environmental Health Sciences MIT, Massachusetts Institute of Technology

Attendee Testimonials

Hear what your peers had to say about the leading event in Bioconjugation:

"Great variety of bioconjugation modalities. I'm sure this sort of crosstalk will create new innovations." - Roger Pak, Pfizer

"An all-encompassing smorgasbord to provide a really comprehensive update on what is happening in the biologics space" - Catherine Hutchings, Principal Scientist, Antibody Discovery, Heptares Therapeutics

"This is an outstanding venue for bringing together experts in the field, vendors, scientists and other interested parties, and the collaborative and open environment has always been rewarding. This meeting is on my calendar every year!" - Gene Lee, Ph.D., Director, Protein and Cell Sciences, EMD Serono